Search
Close this search box.

ProsTAV®

PROSTAV®: TELOMERIC BIOMARKER FOR EARLY DIAGNOSIS OF PROSTATE CANCER

In vitro diagnostic medical device.
Increases the safety and health of patients at risk of prostate cancer.

WHAT IS

?

The new telomere-based biomarker, which requires only a simple blood sample, relates the telomeric profile to the likelihood of significant prostate cancer (PCa) for patients with PSA 3-10 ng/ml.

ProsTAV® provides three types of results: the ProsTAV score and the probabilities of Gleason ≥ 7 and Gleason ≥ 8 associated with this score, with which the clinician can establish the need for confirmatory biopsy for patients with ProsTAV score > 10%.

Following an observational clinical study in a cohort of 1,043 samples, it has been shown that the ProsTAV® biomarker avoids 33% of biopsies, which represents a great saving in healthcare resources.

PROSTAV® RESULTS

Following an observational clinical study in a cohort of 1,043 samples, it has been demonstrated that the ProsTAV® biomarker avoids 33% of biopsies and helps the clinician to evaluate patients at low risk of PCa, thus prioritizing those who require other diagnostic tests.

71%

AUC

90%

Sensitivity

33%

Specificity

33%

% in reduction of unnecessary biopsies

91%

NPV

29%

PPV

10%

Misclassified significant cancer: Gleason 7 (3+4)

0%

Misclassified significant cancer: Gleason 8

Figure 1

ROC curve analysis shows the performance of the ProstTAV model in the validation cohort, compared to PSA and free PSA%. AUC, area under the curve; CI, confidence interval; PSA, prostate specific antigen.

ADVANTAGES OF THE TEST

Early detection of prostate cancer is essential for successful treatment and long-term survival.

Play Video
Access prostate cancer information with our downloadable brochures
Prostate Cancer information for patients – Life Length Laboratories
Biomarker for early Prostate Cancer diagnosis – Life Length Laboratories
  1. Cáncer de Próstata – SEOM: Sociedad Española de Oncología Médica. (n.d.)., from Casos nuevos por año son diagnosticados en España.
  2. Sung, H., et al. (2021). Global CancerStatistics 2020: https://doi.org/10.3322/CAAC.21660
  3. Dimensiones del cáncer | AECC Observatorio. (n.d.). from Casos nuevos por año son diagnosticados en España.
  4. Xu, J., et al. (2020). Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine, 52.
    https://doi.org/10.1016/J.EBIOM.2019.102616
Do you want to know more?
Contact us

DO YOU WANT MORE INFORMATION?

For further information or enquiries please contact oncologydiagnostics@lifelength.com or leave your details on this form.

DO YOU WANT MORE INFORMATION?

For further information or enquiries please contact info@lifelength.com or leave your details on this form.

We inform our valued customer community that we have made the difficult decision to close our General Martinez Campos clinic.

However, we want to assure our customers that Life Length will continue to provide its proprietary telomere measurement services and HealthTAV®, HealthOX and HealthNAD+ assays in more than 35 countries. We will also continue to work closely with physicians and clinics committed to personalised medicine, longevity and healthy ageing.

It is a true privilege and honour to have had the opportunity to serve and assist tens of thousands of clients who have placed their trust in our clinic since the beginning of the pandemic. We express our deepest appreciation.

If you have any questions or queries, please do not hesitate to write to us at info@lifelength.com. We are here to help you in any way we can.

Be part of our team

For further information or enquiries, please leave your details on this form.

DO YOU WANT MORE INFORMATION?

For further information or enquiries please contact clinica@lifelength.com or leave your details on this form.

Our tests

DO YOU WANT MORE INFORMATION?

For further information or enquiries please contact contractresearch@lifelength.com or leave your details on this form.